Toi M - Search Results

1

A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17).

Fukada I, Ito Y, Kondo N, Ohtani S, Hattori M, Tokunaga E, Matsunami N, Mashino K, Kosaka T, Tanabe M, Yotsumoto D, Yamanouchi K, Sawaki M, Kashiwaba M, Kawabata H, Kuroi K, Morita S, Ohno S, Toi M, Masuda N. Fukada I, et al. Among authors: toi m. Breast Cancer Res Treat. 2021 Dec;190(3):425-434. doi: 10.1007/s10549-021-06396-0. Epub 2021 Sep 23. Breast Cancer Res Treat. 2021. PMID: 34554370 Free PMC article. Clinical Trial.

2

Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients.

Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T. Osaki A, et al. Among authors: toi m. Am J Surg. 1992 Oct;164(4):323-6. doi: 10.1016/s0002-9610(05)80897-9. Am J Surg. 1992. PMID: 1357997

3

Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization.

Toi M, Hattori T, Akagi M, Inokuchi K, Orita K, Sugimachi K, Dohi K, Nomura Y, Monden Y, Hamada Y, et al. Toi M, et al. Cancer. 1992 Nov 15;70(10):2475-83. doi: 10.1002/1097-0142(19921115)70:10<2475::aid-cncr2820701014>3.0.co;2-p. Cancer. 1992. PMID: 1423177 Clinical Trial.

4

[Prognostic significance of expression of c-ERBB-2 oncoprotein in breast cancer patients].

Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T. Osaki A, et al. Among authors: toi m. Gan To Kagaku Ryoho. 1991 Jun;18(7):1181-5. Gan To Kagaku Ryoho. 1991. PMID: 1675844 Japanese.

5

Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study.

Toi M, Tominaga T, Osaki A, Toge T. Toi M, et al. Breast Cancer Res Treat. 1994 Jan;29(1):51-8. doi: 10.1007/BF00666181. Breast Cancer Res Treat. 1994. PMID: 7912567 Clinical Trial.

6

Primary squamous cell carcinoma of the breast after cured Hodgkin's disease.

Kuroi K, Osaki A, Yamada H, Toi M, Toge T, Takimoto Y, Kuramoto A, Arihiro K, Inai K. Kuroi K, et al. Among authors: toi m. Surg Today. 1993;23(1):81-4. doi: 10.1007/BF00309006. Surg Today. 1993. PMID: 8461611

7

Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression.

Toi M, Inada K, Suzuki H, Tominaga T. Toi M, et al. Breast Cancer Res Treat. 1995;36(2):193-204. doi: 10.1007/BF00666040. Breast Cancer Res Treat. 1995. PMID: 8534867

8

Metalloproteinases and tissue inhibitors of metalloproteinases.

Toi M, Ishigaki S, Tominaga T. Toi M, et al. Breast Cancer Res Treat. 1998;52(1-3):113-24. doi: 10.1023/a:1006167202856. Breast Cancer Res Treat. 1998. PMID: 10066076 Review.

9

[Docetaxel as a single agent in cases of advanced/recurrent breast cancer previously treated with anthracycline].

Nagai S, Toi M, Kuroi K, Hayashi K, Tominaga T. Nagai S, et al. Among authors: toi m. Gan To Kagaku Ryoho. 1999 Nov;26(13):2037-42. Gan To Kagaku Ryoho. 1999. PMID: 10584568 Clinical Trial. Japanese.

10

[Antiangiogenesis therapy and hormone therapy--their resemblance and applications of prognostic and predictive factors].

Toi M, Matsumoto G, Bando H, Kuroi K. Toi M, et al. Gan To Kagaku Ryoho. 2000 Jul;27(8):1212-6. Gan To Kagaku Ryoho. 2000. PMID: 10945019 Japanese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

788 results

Search Page

Filters